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Summary
The effects of hormone replacement therapy (HRT) on thrombosis
risk, thrombotic variables, and the inflammatory marker C-reactive
protein (CRP) may vary by route of administration (oral versus trans-
dermal). We studied the relationships of 14 thrombotic variables (pre-
viously related to cardiovascular risk) and CRP to menopausal status
and to use of HRT subtypes in a cross-sectional study of 975 women
aged 40-59 years. Our study confirmed previously-reported associa-
tions between thrombotic variables and menopausal status. Oral HRT
use was associated with increased plasma levels of Factor IX, activated
protein C (APC) resistance, and CRP; and with decreased levels of tis-
sue plasminogen activator (t-PA) antigen and plasminogen activator in-
hibitor (PAI) activity. Factor VII levels were higher in women taking
unopposed oral oestrogen HRT. The foregoing associations were not
observed in users of transdermal HRT; hence they may be consequen-
ces of the “first-pass” effect of oral oestrogens on hepatic protein 
synthesis. We conclude that different effects of oral and transdermal
HRT on thrombotic and inflammatory variables may be relevant to
their relative thrombotic risk; and suggest that this hypothesis should be
tested in prospective, randomised studies.
Introduction
The risk of cardiovascular disease, especially ischaemic heart dis-
ease (IHD) increases after the female menopause. Observational studies
suggest that hormone replacement therapy (HRT) decreases the risks of
IHD and total mortality (1-3). Possible mechanisms for these associa-
tions include changes in blood lipids, blood pressure and insulin resis-
tance; they also include changes in haematological variables related to
thrombotic risk through their roles in blood coagulation, fibrinolysis or
blood flow (rheology) (3, 4). Recently, case-control studies as well as
clinical trials have shown that HRT increases the risk of venous throm-
boembolism 2-4 fold (5-10). One trial also suggested an early increase
in risk of myocardial infarction in women with IHD who take HRT
(10). The mechanisms for increased arterial and venous thrombotic risk
are not defined, but may include acquired resistance to activated protein
C (APC), which we have recently proposed as a common mechanism
through which several genetic or acquired risk factors (including HRT)
may promote venous thrombosis (11).
In recent years, transdermal HRT preparations are increasingly pre-
scribed. Their potential advantages include acceptability; provision of
relatively constant physiological levels of oestradiol while avoiding un-
naturally high plasma levels of oestrogen and other metabolites; and
avoiding the metabolic consequences of the high hormone concentra-
tions in the hepatic portal vein following oral HRT, which include the
hepatic synthesis of proteins involved in coagulation, fibrinolysis and
the acute-phase response (12). Few comparisons of oral and transder-
mal HRT have been reported (3, 4, 12-14); however they suggest poten-
tially important differences in their effects on coagulation and fibrino-
lysis.
The aim of the present study was to examine the relationships of 14
thrombotic variables which have previously been related to risk of IHD
and/or venous thromboembolism (15) to menopausal status and to use
of oral or transdermal HRT, in a cross-sectional study of women aged
40-59 years who participated in a family study of cardiorespiratory dis-
ease (Midspan Family Study) in the West of Scotland (16). Further-
more, we sought to examine the extent to which any such relationships
might be explained by changes in blood lipids or lipoproteins (15, 17,
18) or by acute-phase reactants, as measured by serum levels of C-reac-
tive protein (CRP) (19).
Subjects and Methods
The eligible population for the Midspan Family Study were offspring aged
30-59 years of parents who participated during middle-age in a general popula-
tion study between 1972-1976, the Renfrew-Paisley (Midspan) Study (20).
3,202 such offspring were identified who lived within 45 min travel of the Ren-
frew-Paisley area, of whom 1,040 men and 1,298 women completed a question-
naire and examination: a response rate of 73% from the eligible population
(16). The study was approved by the appropriate local research ethics commit-
tees, and all participants gave their written informed consent. Besides demo-
graphic and lifestyle information, for women, the questionnaire included ques-
tions on pregnancy, menopausal status, and use and type of HRT or oral contra-
ceptives. On the day they attended for venepuncture participants were asked
whether they had suffered from any infections in the previous seven days; there
were specific questions about suffering from a sore throat, cold or influenza.
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There were 1056 women aged 40-59, of whom 965 had complete questionnaire
data, underwent venepuncture, were not pregnant nor taking oral contraception,
and were not on warfarin therapy. The sample also included 10 women aged
30-39 with an early menopause who met the same criteria. Examination includ-
ed height and weight, for calculation of body mass index, BMI = weight (kg)/
height (m)2.
A non-fasting venous blood sample was taken for measurement of plasma
lipids (total cholesterol, triglyceride and HDL cholesterol; according to the 
Lipid Research Clinics Manual of Laboratory Operations) and CRP (ELISA,
standardised using the International Reference Standard Lot 91/0619) in the In-
stitute of Biochemistry, Glasgow Royal Infirmary. Thrombotic variables were
measured in the University Department of Medicine, Glasgow Royal Infirmary.
Plasma viscosity, microhaematocrit, whole blood viscosity (calculated from
plasma viscosity and haematocrit) and white cell count were measured in fresh,
dipotassium edetate (1.5 mg/ml) anticoagulated blood as previously described
(21). Plasma fibrinogen, factor VII, factor VIII and factor IX (22); activated
partial thromboplastin time (APTT) and activated protein C (APC) ratio (11);
tissue plasminogen activator (t-PA) antigen, plasminogen activator inhibitor
(PAI) activity, and fibrin D-dimer antigen (23); and von Willebrand factor anti-
gen (24) were measured in citrated plasma (0.11 M trisodium citrate; 9 : 1 v : v)
as previously described. Allowance was made for potential carriers of the fac-
tor V Leiden mutation by repeating statistical analyses, after excluding subjects
who showed lack of correction of a low APC ratio (less than 2.15) when the 
assay was repeated in factor V deficient plasma. 
Data were analysed using S-Plus for Windows v4.5. Each response variable
was modelled using multiple linear regression to look for differences between
women not on HRT (before or after menopause) and women on HRT (catego-
rized primarily according to whether the route of administration was oral or
transdermal, and secondarily whether the oestrogen was opposed or unopposed
by progestogen). Each model also included a term for a linear age effect, re-
gardless of whether or not it was statistically significant. Analyses were repeat-
ed after including a term for duration of HRT use. If necessary, response vari-
ables were transformed so that the models produced roughly normally distrib-
uted residuals. In most cases, the response was log transformed, except for
white cell count which was given a square root transformation, and haemato-
crit, APC ratio, PAI and D-dimer which were left untransformed. Tests of 
significance and 95% confidence intervals were not adjusted for multiple 
comparisons; however, we adjusted for clustering of siblings within the same
family by using generalised estimating equations.
Each logistic regression model provided age-adjusted effect estimates (with
standard errors) of differences between subject groups. 95% confidence inter-
vals were calculated by adding and subtracting 1.96 standard errors from each
effect estimate. No adjustments were made for multiple testing. For untrans-
formed variables these estimates and confidence intervals are directly interpret-
able as differences between group averages. For variables that were log trans-
formed, the estimates and confidence intervals were back transformed by tak-
ing exponentials to give ratios between groups, and these were then converted
into percentage differences, by subtracting 1 and multiplying by 100.
Results
Risk Factor Variables (Table 1)
After defined exclusions, analyses were performed on up to 522 pre-
menopausal women (periods, no HRT); 222 post-menopausal women
(no periods) not currently taking HRT; and 231 women currently taking
HRT. Of the latter, 183 were taking oral HRT (58 taking unopposed
oestrogen; 125 taking combined oestrogen and progestogen) and 48
were taking transdermal HRT (35 taking unopposed oestrogen, and 13
taking combined oestrogen and progestogen). As expected, there were
small but statistically significant differences in age and smoking habit
between premenopausal and postmenopausal women (Table 1); but
there were no significant differences in age or smoking between 
women on oral HRT and those on transdermal HRT. However, users of
unopposed oral HRT were younger than users of combined oral HRT
(effect estimate – 2.65 years; 95% CI – 4.01, – 1.30; p <0.001). As not-
ed in the Methods section, all comparisons were age-adjusted.
There were no significant differences in body mass index between
subject groups. There were significant postmenopausal increases in se-
rum cholesterol, triglyceride and total cholesterol/HDL ratio. Overall,
HRT use (oral or transdermal) was not associated with changes in tri-
glyceride; however oral HRT appeared to partly reduce the postmeno-
pausal increase in cholesterol, and also prevented the postmenopausal
increase in total cholesterol/HDL ratio (Table 1). The only significant
difference in serum lipids between oral HRT users and transdermal
HRT users was a lower HDL cholesterol level in transdermal HRT 
Table 1 Age, smoking habit, body mass index (BMI) and serum lipids in subject groups. IQR = inter-quartile range; a = significant difference relative to
“Periods, No HRT” group; b = significant difference relative to “No Periods, No HRT” group; * = p 0.05; ** = p 0.01; *** = p 0.001. Raw data with age-
adjusted significance tests (except for age)
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users (effect estimate – 7.9%; 95% CI – 14.8, – 0.54; p = 0.036).
Among oral HRT users, those using unopposed oestrogens had higher
median levels of cholesterol (8.3%; 95% CI 2.8, 14.0; p = 0.0027), tri-
glyceride (24.6%, 95% CI 7.7, 44.3; p = 0.0032) and HDL cholesterol
(17.0%; 8.0, 26.8; p = 0.0001). There was no significant difference in
total cholesterol/HDL ratio (-8.0%; 95% CI – 16.8, 1.6; p = 0.10). There
were no significant differences in serum lipids comparing users of
transdermal opposed oestrogen and users of transdermal unopposed
oestrogen. 
Coagulation Factors (Table 2)
Plasma fibrinogen was significantly higher in postmenopausal wom-
en compared to premenopausal women. HRT had no significant effect
on plasma fibrinogen. There was no significant difference in fibrinogen
levels between users of oral HRT and users of transdermal HRT, with
or without adjustment for smoking habit as well as age (p = 0.74).
Factor VII and Factor IX levels were also significantly higher in
post-menopausal compared to pre-menopausal women. Users of trans-
dermal HRT had similar factor VII levels to premenopausal women.
The effect of oral HRT on factor VII levels differed according to HRT
type: higher median levels were seen in users of unopposed oral oestro-
gen (139 iu/dl; IQR 125,163) than in users of combined oral oestrogen,
who also had similar levels to premenopausal women (114 iu/dl; 
IQR 101,132) (effect estimate + 26.0%; 95% CI 17.6, 34.9; p 0.0001).
This effect was similar after adjustment for triglyceride and total cho-
lesterol levels and body mass index (+21.7%; 14.3, 29.6, p 0.0001).
The effect of HRT on factor IX levels also differed by HRT type:
higher levels compared to postmenopausal women not taking HRT
were seen in users of oral HRT, while use of transdermal HRT was as-
sociated with significantly lower levels compared to use of oral HRT
(effect estimate – 12.5%; 95% CI – 18.3, – 6.2; p = 0.0002), which were
similar to those in premenopausal women.
Factor VIII and von Willebrand factor antigen did not vary signifi-
cantly with menopause or HRT, apart from a slightly lower factor VIII
level in users of transdermal HRT compared to post-menopausal wom-
en not using HRT (Table 2). Users of transdermal HRT also had a
slightly lower level of factor VIII than users of oral HRT (effect esti-
mate – 9.7%; 95% CI – 18.6, 0.2; p = 0.055).
APTT and APC ratio (Table 3)
A small increase in APTT was observed after the menopause, with a
further increase in users of transdermal HRT. APTT was longer in 
users of transdermal HRT than in users of oral HRT (effect estimate
4.1%; 95% CI 1.2, 7.0; p = 0.0052). This effect was reduced on multi-
Table 2 Coagulation factors in subject groups. IQR = inter-quartile range; a = significant difference relative to “Periods, No HRT” group; b = significant
difference relative to “No Periods, No HRT” group; * = p 0.05; ** = p 0.01; *** = p 0.001. Raw data with age-adjusted significance tests
Table 3 APTT, APC ratio and fibrinolytic variables in subject groups. IQR = inter-quartile range; a = significant difference relative to “Periods, No HRT” group;
b = significant difference relative to “No Periods, No HRT” group; * = p 0.05; ** = p 0.01; *** = p 0.001. Raw data with age-adjusted significance tests
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variate analysis including factor VIII and factor IX levels (2.36%;
–0.00, 4.84; p = 0.053). 
APC ratio did not vary with menopause, but was significantly lower
in the oral HRT group compared to pre-menopausal women and post-
menopausal non-users of HRT. This effect was similar in users of un-
opposed oral HRT (2.59; IQR 2.33, 2.80) and combined oral HRT
(2.64; IQR 2.45, 2.84); but was not seen in users of transdermal HRT.
APC ratio was higher in users of transdermal HRT compared to users of
oral HRT (effect estimate 0.11 (absolute change); 95% CI 0.02, 0.21; 
p = 0.019). This effect was attenuated only slightly in a multivariate
analysis that included factor VIII and factor IX levels (effect estimate
0.09; -0.01, 0.18; p = 0.070), and in a repeat analysis excluding the 
28 subjects who were potential carriers of the V Leiden mutation as 
defined in the Subjects and Methods section (0.08; – 0.01, 0.18; 
p = 0.073). The effect of oral HRT on APC ratio compared to post-meno-
pausal non-users of HRT remained similar on multivariate analysis 
including these variables (-0.10 absolute units; 95% CI -0.16, -0.03, 
p = 0.0052), as did the lack of effect of transdermal HRT compared to
post-menopausal non-users of HRT (effect estimate – 0.01 absolute
units; –0.11, 0.19; p = 0.80).
Fibrinolytic Variables (Table 3)
t-PA antigen and PAI activity were higher in post-menopausal com-
pared to pre-menopausal women; and were significantly lower in oral
HRT users compared to both pre-menopausal women and post-meno-
pausal non-users. This effect was greater in users of unopposed oral
HRT (median t-PA 5.55 ng/ml; IQR 3.85, 6.9; PAI 69% pool; 57, 85)
than in users of combined oral HRT (median t-PA 6.2 ng/ml; IQR 4.47,
8.62; PAI 75% pool; 63, 88); and was statistically significant for t-PA
(effect estimate – 95% CI 14.1%; -25.2, – 1.3; p = 0.033) but not for
PAI (p = 0.22). t-PA levels were significantly higher in users of trans-
dermal HRT compared to users of oral HRT (effect estimate 17.4%;
95% CI 2.1, 35.0; p = 0.024), and this effect was similar after adjust-
ment for triglyceride and total cholesterol levels and body mass index
(18.4%; 3.0, 36.1; p = 0.018). PAI levels were also significantly higher
in users of transdermal HRT compared to users of oral HRT (effect es-
timate 16.5% pool; 95% CI 6.1, 26.8; p = 0.0018), and again this effect
was similar after adjustment for triglyceride and total cholesterol levels
and body mass index (16.5% pool; 5.9, 27.1; p = 0.0023). t-PA and PAI
levels in transdermal HRT users were similar to levels in non-users of
HRT.
No significant effects of menopause or HRT use on D-dimer were
observed.
C-reactive Protein, White Cell Count, Haematocrit and Viscosity 
(Table 4)
There were no significant associations of the menopause with CRP
or white cell count. Oral HRT use was overall associated with signifi-
cant increases in CRP. This effect was similar in users of unopposed
oral HRT (median 2.40 ng/ml; IQR 0.95, 5.10) and in users of com-
bined oral HRT (median 2.06 ng/ml; IQR 0.79, 4.44); but was not ob-
served in users of transdermal HRT. CRP levels were significantly low-
er in users of transdermal HRT compared to users of oral HRT (effect
estimate – 50.7%; 95% CI – 69.1, –21.2; p = 0.0031), and were similar
after adjustment for smoking habit and history of recent infection 
(–50.3%; – 68.9, – 20.7; p = 0.0034).
Haematocrit, blood viscosity and plasma viscosity were each sig-
nificantly higher in post-menopausal compared to pre-menopausal
women. The post-menopausal increases in plasma and blood viscosity
(but not haematocrit) were reduced by use of oral HRT; but not by
transdermal HRT use. Haematocrit was higher in users of transdermal
HRT compared to users of oral HRT (effect estimate 1.04 haematocrit
%; 95% CI 0.03, 2.04; p = 0.044), and there was a similar but non sig-
nificant trend, for blood viscosity (effect estimate 2.4%; – 0.10, 4.98; 
p = 0.061).
Duration of Use
Mean duration of use was 3.7 (SEM 0.2) years in the oral HRT group
and 4.1 (SEM 0.5) years in the transdermal HRT group. No significant
effects of duration of HRT use on the above results were observed (data
not shown). Hence data are presented unadjusted for duration of use.
Discussion
We have shown that oral HRT use (but not transdermal HRT use) is
associated with increased plasma levels of factor IX, APC resistance,
and CRP; and with decreased levels of t-PA antigen and PAI activity.
Table 4 C-reactive protein, white cell count, viscosity and haematocrit in subject groups. IQR = inter-quartile range; a = significant difference relative to Periods,
No HRT group; b = significant difference relative to No Periods, No HRT group; * = p 0.05; ** = p 0.01; *** = p 0.001. Raw data with age-adjusted signif-
icance tests
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The first three of these findings may be relevant to the increased risk of
venous thromboembolism in users of oral HRT; which we have recent-
ly shown to be highest in women with high factor IXc, APC resistance,
or low antithrombin activity (25). We suggest that the lack of effect of
transdermal HRT on these variables be confirmed in further, larger
studies (prospective as well as cross-sectional). If confirmed, such dif-
ferences in effects may be one factor to consider when prescribing HRT
to women with thrombophilias.
Effects of Menopause
We confirmed several potentially adverse effects of the female meno-
pause (after age-adjustment) on thrombotic variables related to risk of
IHD: increased blood viscosity, partly due to increases in haematocrit,
and partly to increased plasma viscosity (21), which in turn reflected in-
creases in fibrinogen and lipids (3, 4, 21, 22, 26). These rheological ef-
fects of the menopause were not associated with significant increases in
markers of acute-phase reactions such as white cell count or C-reactive
protein (19, 21). Increases in factors VII and IX; and increases in the fib-
rinolytic inhibitor PAI-1 (and in t-PA antigen, which probably reflects
inactive PAI-1 – t-PA complexes) were also observed, confirming pre-
vious studies (3, 4, 13, 14, 22). No effect of menopause was observed
on the factor VIII: von Willebrand factor complex, or on fibrin 
D-dimer.
Effects of HRT-Coagulation
Plasma fibrinogen levels were similar in users of oral HRT com-
pared to premenopausal women in the present study, as in previous ob-
servational studies and randomised trials, which show a fibrinogen-
lowering effect of oral HRT (3, 4, 14, 25, 27, 28). In contrast, users of
transdermal HRT in the present study had similar levels of fibrinogen to
post-menopausal non-users of HRT, consistent with previous reports
(14). However the difference between users of oral HRT and users of
transdermal HRT was not statistically significant, whether or not smok-
ing was adjusted for as well as age.
Overall, factor VIIc levels were similar in users of oral HRT and in
postmenopausal non-users of HRT. However, we observed that users of
oral unopposed oestrogen had significantly higher levels, while users of
combined oestrogen-progestogen HRT had significantly lower levels.
These findings suggest (a) that unopposed oestrogen exerts a significant
“first pass” effect on hepatic synthesis of factor VII (12); and (b) that
progestogens significantly modify the effects of oestrogen in increasing
factor VII. The latter effect has also been observed in another cross-sec-
tional study (27) and in a randomized trial (28). Because of the impor-
tant effects of cholesterol and triglyceride on factor VII antigen and ac-
tivity (15, 17, 18), it has been suggested that differences between factor
VII levels in users of different oral HRT preparations may partly reflect
different effects of such preparations on blood lipids (29). However in
the present study, adjustment for total cholesterol, triglycerides and
body mass index did not explain these differences. We did not study the
influence of factor VII genotypes on factor VII levels in the present
study. We observed no significant effect of transdermal HRT use on
factor VII levels compared to premenopausal women, consistent with
previous reports (14).
We confirmed that use of oral HRT increases factor IX levels, com-
pared to postmenopausal non-users of HRT (22). We observed no sig-
nificant effect of transdermal HRT use on factor IX levels compared to
premenopausal women not using HRT, consistent with a previous re-
port (14). This difference in factor IX levels between users of oral and
transdermal HRT appeared to contribute to the difference in APTT 
levels observed in the present study.
We observed little overall effect of HRT use on factor VIII or von
Willebrand factor levels in the present study, consistent with most pre-
vious reports (3, 4, 14, 22, 27). However, we observed that users of
transdermal HRT had a lower level of factor VIII than users of oral
HRT, which while of borderline statistical significance appeared to
contribute to the difference in APTT levels observed in the present
study. We did not study the influence of blood group on factor VIII or
von Willebrand factor levels.
We have confirmed that HRT use is associated with increased APC
resistance, as shown by a lower APC ratio (11). In the present study, we
have shown (a) that this association is similar in users of oral unop-
posed oestrogen HRT and in users of oral combined HRT; and (b) that
this association was not present in users of transdermal HRT. These re-
sults were unaffected when we excluded subjects with a phenotype 
(lack of correction of low APC ratio when repeated in factor V deficient
plasma) which is correlated with the factor V Leiden genotype. Our
finding that 3% of women in the West of Scotland were potential car-
riers of V Leiden by this screening assay is very similar to our previous
findings in this population using DNA analysis (11). Our observation of
the lack of effect of transdermal HRT use on APC resistance has recent-
ly been confirmed in a prospective study, which indeed suggested a
beneficial effect of transdermal HRT on APC resistance, possibly as a
result of decreased factor VIII:c levels (30).
Effects of HRT-Fibrinolysis
We have confirmed previous reports (13, 14, 31) that oral HRT use,
but not transdermal HRT use, is associated with lower levels of PAI 
activity and t-PA antigen compared to post-menopausal non-users of
HRT. These effects of oral HRT may reflect a “first-pass” effect on
hepatic PAI-1 synthesis (12). While both PAI-1 and t-PA antigen
show significant associations with plasma total cholesterol and trigly-
ceride levels, obesity, and insulin resistance (15, 17, 18), we observed
no effect of adjustment for these lipid variables (and body mass index)
on the effect of oral HRT on PAI activity or t-PA antigen in the present
study. We did not observe any relationships of reduced PAI levels in
oral HRT users to increased fibrin D-dimer levels, in contrast to a pre-
vious report (31). While reductions in PAI and t-PA antigen levels with
oral HRT use have been postulated as potentially beneficial (13, 31),
this hypothesis has not yet been tested in controlled trials of PAI-1
reduction.
Effects of HRT-CRP, White Cell Count, Haematocrit and Viscosity
We observed that oral HRT (but not transdermal HRT) significantly
increases plasma C-reactive protein, a marker of the hepatic protein re-
sponse to inflammation. This observation is consistent with two recent
reports (32, 33) and may reflect oestrogenic effects on inflammatory
monokines such as tumour necrosis factor and interleukin-6 (21, 34). It
is possible that increases in acute-phase reactant proteins may be a
cause of low APC ratios: ceruloplasmin may modulate APC resistance
(35). The lack of effect of transdermal HRT on CRP may be relevant to
risk of IHD, because CRP levels within the normal range are predictors
of IHD in healthy men and women (36, 37). No effect of HRT use (oral
or transdermal) on blood white cell count was observed, which suggests
that the effect of oral oestrogens on CRP is due to an effect on hepatic
synthesis of reactant plasma proteins, rather than a generalised inflam-
matory response.
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Blood viscosity and its major determinants (plasma viscosity and
haematocrit) are predictors of IHD and stroke in epidemiological stud-
ies (38). It has been suggested that the lower risk of IHD in premeno-
pausal women may be partly due to their lower levels of these variables
(21). We have confirmed two other recent reports from cross-sectional
studies (21, 26) that oral HRT reduced the post-menopausal increases
in plasma and blood viscosity. This effect was not observed in users of
transdermal HRT in the present study.
Strengths and Limitations of Study
Strengths of this cross-sectional study, as with others (27), include
the sampling of HRT users and non-users from the general population
rather than secondary or tertiary care; the collection of a range of
demographic, lifestyle, physiological and laboratory variables obtained
using identical methods in HRT users and non-users; participants’ lack
of knowledge of the detailed scientific questions under investigation
because of the broad base of the study; and blinding of laboratory staff
to participants’ HRT status. Limitations of this study include the lack of
information about hormonal dose (because women were asked only to
name the brand and duration of use of the HRT that they were taking),
factor VII and factor V Leiden genotypes, and blood group. Multiple
comparisons were made, hence p-values between 0.05 and 0.01 should
be viewed with caution. We therefore suggest that further, larger 
studies be performed to confirm the lack of effect of transdermal HRT
on risk markers for thrombosis, which may have implications for their
consideration in women at increased risk of thrombosis.
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